Zacks Investment Research on MSN13h
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung CancerJ&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback